Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor

Trial Profile

A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rucaparib (Primary) ; Rucaparib (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Epirubicin; Paclitaxel; Pemetrexed
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Clovis Oncology [CEASED]; zr pharma
  • Most Recent Events

    • 01 May 2022 Results of population pharmacokinetics model Study 1014 (NCT01009190), Study 10 (NCT01482715), and ARIEL2 (NCT01891344) published in the Cancer Chemotherapy and Pharmacology
    • 18 Mar 2017 Results of population pharmacokinetics of Rucaparib developed from A4991014 (n=35), NCT01482715 (n=124) and NCT01891344 (n=300) and 2 other studies, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 12 Feb 2017 Results published in the British Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top